Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

3.45
-0.1100-3.09%
Post-market: 3.510.0600+1.74%19:44 EDT
Volume:898.03K
Turnover:3.15M
Market Cap:149.37M
PE:-4.45
High:3.61
Open:3.52
Low:3.44
Close:3.56
52wk High:5.06
52wk Low:1.62
Shares:43.30M
Float Shares:36.46M
Volume Ratio:1.04
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7754
EPS(LYR):-1.3374
ROE:-682.61%
ROA:-63.99%
PB:-878.65
PE(LYR):-2.58

Loading ...

NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG

Dow Jones
·
Aug 18

NRX Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 17

NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate

Benzinga Earnings
·
Aug 17

NRX Pharmaceuticals (Nasdaq:Nrxp) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17TH at 4:30Pm Et

THOMSON REUTERS
·
Aug 17

NRX Pharmaceuticals - Reports Cash and Cash Equivalents of $26.70 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 17

Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

Dow Jones
·
Aug 17

NRx Pharma Q2 FY26 Net Loss Narrows to $16.52 Million; Revenue Rises to $1.1 Million

Reuters
·
Aug 15

NRX Pharmaceuticals Inc Expected to Post Earnings of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 14

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

GlobeNewswire
·
Aug 08

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

TIPRANKS
·
Aug 08

NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review

Dow Jones
·
Aug 08

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

TIPRANKS
·
Aug 07

FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval

Reuters
·
Aug 07

NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS
·
Aug 07

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS
·
Aug 07

NRX Pharmaceuticals - on July 21, Nrxd Selected by Darpa for Negotiation of Potential Sparc-tms Clinical Trial Award - SEC Filing

THOMSON REUTERS
·
Jul 22

Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Simply Wall St.
·
Jul 16

Nrx Pharmaceuticals Pushes Kadima Dispute into Arbitration Amid Acquisition Lawsuit

Reuters
·
Jun 26